Page last updated: 2024-09-04

cyc 682 and Acute Disease

cyc 682 has been researched along with Acute Disease in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	0 (0.00)	29.6817
2010's	1 (100.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Boone, PA; Chiao, JH; Cortes, J; Faderl, S; Garcia-Manero, G; Green, SR; Kantarjian, H; O'Brien, S; Plunkett, W; Ravandi, F; Westwood, R	1

Trials

1 trial(s) available for cyc 682 and Acute Disease

Article	Year
Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-10, Volume: 28, Issue:2 Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cytosine; Drug Administration Schedule; Humans; Leukemia; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Survival Analysis	2010

Article

Year

Phase I clinical and pharmacokinetic study of oral sapacitabine in patients with acute leukemia and myelodysplastic syndrome.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Jan-10, Volume: 28, Issue:2

Topics: Acute Disease; Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Arabinonucleosides; Cytosine; Drug Administration Schedule; Humans; Leukemia; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Survival Analysis

2010